Use the hyperlinks, where available to access additional clinical trial information.
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)
Approximately 140 people will be enrolled and screening to ensure that up to approximately 126 evaluate patients can be assigned to study treatments across all three study arms. Eligible participants will be non-randomly assigned two one of three experimental arms. In Experimental Arm 1, participants will receive an oral dose of AZD5305 and oral dose of Enzalutamide once daily. In Experimental Arm 2, participants will receive an oral dose of AZD5305 and an oral dose of Abiraterone Acetate once daily. In Experimental Arm 3, participants will receive an oral dose of AZD5305 once daily and an oral dose of Darolutamide twice daily.